In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Prometheus gets US rights to Novartis' Proleukin

Executive Summary

Just weeks after executing a $260mm credit facility, Prometheus Laboratories (cancer and gastrointestinal therapeutics and diagnostics) is using some of those proceeds to license exclusive US marketing and distribution rights to Novartis' marketed drug Proleukin (aldesleukin), a recombinant IL-2 protein for adults with metastatic melanoma and metastatic kidney cancer.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Reverse Licensing

Related Companies